Werewolf Therapeutics - HOWL Income before deduction of interest, taxes and amortization
Werewolf Therapeutics (HOWL) is fighting for leadership in cancer immunotherapy, contending with industry behemoths possessing colossal resources. The efficiency of PREDATOR drug development is increasing through the application of AI and robotics. External laboratories assist in testing, while the firm retains all patents. An analysis of absolute EBITDA allows for an assessment of operating income, with the current mark equal to 0.00.
Werewolf Therapeutics, Inc. - analytical breakdowns and key metrics (HOWL)
- market value and analyst target forecast:
- issuer market value details:
- book capitalization information:
- business debt structure and liquidity details:
Total Debt to Equity Ratio Werewolf Therapeutics|HOWL - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Werewolf Therapeutics Inc.|HOWL - Company Debts|Debt to Book Value Ratio Werewolf Therapeutics|HOWL - Company Long-Term Debt|Short-Term Debt Werewolf Therapeutics|Critical Liquidity werewolftx.com
- company profitability and valuation multiples indicators:
HOWL - Net Income|Future Net Profit Werewolf Therapeutics|HOWL - P/E Multiple|Future Price to Earnings Multiple Werewolf Therapeutics Inc.|HOWL - PEG Multiple|Company Value to EBITDA Werewolf Therapeutics|HOWL - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Werewolf Therapeutics|HOWL - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth werewolftx.com|HOWL - Earnings per share growth in current year|Net earnings per share change forecast for next year Werewolf Therapeutics
Analysis of all company metrics:Werewolf Therapeutics - HOWL
Absolute operating profit reflects the actual cash flow from core operations, allowing investors to distinguish a temporary downturn from a systemic decline in business efficiency. An analysis of historical EBITDA_Co data within the context of biomolecule screening automation at Werewolf Therapeutics (HOWL) helps assess the extent to which laboratory robotization reduces costs and stabilizes yields, confirming the asset's fundamental resilience.
Competitors of Werewolf Therapeutics (HOWL)
NantKwest (IBRX) - Profit before interest, taxes and amortization|IMCR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization JANX (januxrx.com)|RCUS: Operating profit EBITDA|ZYME - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Tango Pharma|Operating profit before deduction of amortization Iovance Corp (IOVA)|Profit before payment of interest, taxes and amortization Immatics N.V. (IMTX)|Operating profit before deduction of amortization xencor.com XNCR|Compass Therapeutics, Inc. - Operating profit before deduction of amortization|Operating profit EBITDA Replimune Group Inc REPL|LYEL - Profit before payment of interest, taxes and amortization|IPHA (Innate Pharma S.A) - Operating profit before amortization|pyxisoncology.com (PYXS) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Compugen (CGEN)|Operating profit before deduction of amortization IOBT|STRO - Operating profit before depreciation charges|Operating profit before deduction of amortization INKT (MiNK)|Company profit before taxes, interest and amortization IMMX|Operating profit EBITDA ALXO (ALX Oncology)|Income before deduction of interest, taxes and amortization CUE|PDS Biotechnology Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Sonnet BioTherapeutics|MAIA Biotechnology Inc (MAIA) - Profit before payment of interest, taxes and amortization|Liminatus - Income before deduction of interest, taxes and amortization|LVTX (LAVA Therapeutics NV) - Operating profit EBITDA|Operating profit EBITDA nextcure.com|Profit before payment of interest, taxes and amortization Leap Therapeutics, Inc. (LPTX)|INTS: Profit before deduction of interest, taxes, depreciation and amortization|Sensei Biotherapeutics, Inc. - Operating profit before deduction of amortization|Theriva Corp (TOVX) - Profit before interest, taxes and amortization|GRTS: Operating profit before deduction of amortization|kinetabio.com (KA) - Operating profit before deduction of amortization|NEXI: Operating profit EBITDA|Profit before interest, taxes and amortization Turnstone Biologics Corp. (TSBX)|Profit before payment of interest, taxes and amortization Vaccinex, Inc|HARP: Income before deduction of interest, taxes and amortization
